Alkermes PLC (ALKS)

50.28
0.06 0.12
NASDAQ : Health Care
Prev Close 50.34
Open 50.42
Day Low/High 50.21 / 50.64
52 Wk Low/High 27.14 / 80.71
Volume 25.27K
Avg Volume 748.80K
Exchange NASDAQ
Shares Outstanding 153.66M
Market Cap 7.78B
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes Announces 2nd Annual Competitive Grants Program To Support Those Affected By Mental Health And Substance Use Disorders

Alkermes Announces 2nd Annual Competitive Grants Program To Support Those Affected By Mental Health And Substance Use Disorders

Alkermes plc (NASDAQ: ALKS) today announced that the company is now accepting applications for the 2 nd annual ALKERMES INSPIRATION GRANTS ® initiative.

Alkermes To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Alkermes To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its Chief Financial Officer, James Frates, will participate in a fireside chat at the Morgan Stanley 15 th Annual Global Healthcare Conference on Monday, Sept.

Alkermes To Present Clinical And Real-World Data At Upcoming 30th Annual Psych Congress

Alkermes To Present Clinical And Real-World Data At Upcoming 30th Annual Psych Congress

Alkermes plc (NASDAQ:ALKS) today announced the presentation of 11 posters highlighting clinical and real-world data pertaining to the company's schizophrenia, opioid dependence and depression portfolios at the...

Alkermes Initiates Rolling Submission Of ALKS 5461 New Drug Application For Major Depressive Disorder

Alkermes Initiates Rolling Submission Of ALKS 5461 New Drug Application For Major Depressive Disorder

Alkermes plc (NASDAQ:ALKS) today announced the initiation of its rolling submission of a New Drug Application (NDA) to the U.

Alkermes Plc Reports Second Quarter 2017 Financial Results

Alkermes Plc Reports Second Quarter 2017 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the second quarter of 2017.

Alkermes To Host Conference Call To Discuss Second Quarter 2017 Financial Results

Alkermes To Host Conference Call To Discuss Second Quarter 2017 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia

Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from ENLIGHTEN-1, the first of two key phase 3 studies in the ENLIGHTEN clinical development program for ALKS 3831, an investigational,...

Alkermes Announces Initiation Of Study 217 For ALKS 5461 For Treatment Of Major Depressive Disorder

Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major...

Alkermes To Present At Goldman Sachs 38th Annual Global Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 38 th Annual Global Healthcare Conference on Thursday, June 15, 2017 at...

Alkermes Announces Initiation Of Phase 3 Study Of ALKS 3831 In Young Adult Patients

Alkermes plc (NASDAQ: ALKS) today announced the initiation of ENLIGHTEN-Early, a supportive study in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel, once-daily, oral atypical...

FDA Approves Two-Month ARISTADA® For Treatment Of Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced that the U.S.

Alkermes' Corporate Presentation To Be Webcast At The Jefferies Healthcare Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies Healthcare Conference on Tuesday, June 6, 2017 at 1:30 p.

Alkermes To Present Data On ALKS 5461 At Upcoming Society Of Biological Psychiatry Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced that data from FORWARD-5 and pooled data from FORWARD-4 and FORWARD-5, two phase 3 studies of ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD),...

Alkermes Announces Completion Of Patient Enrollment In Pivotal Antipsychotic Efficacy Study Of ALKS 3831 For Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in ENLIGHTEN-1, the first of two key phase 3 studies in the ENLIGHTEN clinical development program for ALKS 3831, an investigational, novel,...

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Alkermes Plc Reports First Quarter 2017 Financial Results

Alkermes plc (NASDAQ: ALKS) today reported financial results for the first quarter of 2017.

Alkermes' Corporate Presentation To Be Webcast At The Deutsche Bank 42nd Annual Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 42 nd Annual Health Care Conference on Wednesday, May 3, 2017 at 8:00 a.

Alkermes To Host Conference Call To Discuss First Quarter 2017 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Alkermes To Present Preclinical Data On ALKS 4230 At The American Association For Cancer Research Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced that preclinical data on the company's immuno-oncology drug candidate, ALKS 4230, an engineered fusion protein designed for selective activation of the interleukin-2 (IL-2)...

Alkermes To Present Data On Two-Month Dosing Option Of ARISTADA® At 16th International Congress On Schizophrenia Research

Alkermes plc (NASDAQ: ALKS) today announced that data for the two-month dosing option of ARISTADA ® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia will be...

Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis

Alkermes plc (NASDAQ: ALKS) today announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms of...

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

TheStreet Quant Rating: C- (Hold)